Displaying drugs 10176 - 10200 of 12422 in total
Setiptiline
Setiptiline is a tetracyclic antidepressant (TeCA) which acts as a noradrenergic and specific serotonergic antidepressant (NaSSA). In Japan, the company Mochida started its commercialization for the treatment of depression started in 1989.
Experimental
Matched Description: … In Japan, the company Mochida started its commercialization for the treatment of depression started in …
Didesmethylrocaglamide
Didesmethylrocaglamide is a naturally-occurring derivative of rocaglamide and belongs to a class of anti-cancer phytochemicals referred to as "rocaglamides" derived from plants of the genus Aglaia. While traditionally used for their insecticidal benefits, this class of compounds is now being studied for use as chemotherapeutic agents in the treatment of...
Experimental
Matched Description: … Didesmethylrocaglamide is a naturally-occurring derivative of [rocaglamide] and belongs to a class of ... [A186802,A186763,A186781,A186784] Of the known derivatives of rocaglamide, didesmethylrocaglamide appears ... anti-cancer phytochemicals referred to as "rocaglamides" derived from plants of the genus _Aglaia_. …
Isatoribine
Isatoribine is a selective agonist of TLR7.
Investigational
Matched Description: … Isatoribine is a selective agonist of TLR7. …
Etrolizumab
Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, is typified by a chronic gastrointestinal inflammatory microenvironment, driven in part by the excessive infiltration and retention of intestinal-homing lymphocytes.[A244564, A244569, A244579, A244584] A recent class of drugs designed to impair lymphocyte homing, so-called "anti-trafficking agents" (ATAs), have shown some...
Investigational
Matched Description: … in undesirable blockade of lymphocyte CNS trafficking and reported cases of progressive multifocal leukoencephalopathy ... [A244574] In the case of [natalizumab], which targets the α4 integrin subunit, this has also resulted ... gastrointestinal inflammatory microenvironment, driven in part by the excessive infiltration and retention of …
CX501
Cx501 is used to treat epidermolysis bullosa (EB), a rare genetic condition which can lead to contraction of the joints, fusion of fingers and toes, contraction of the mouth membranes and narrowing of the oesophagus. It is developed by Cellerix and is in phase I of clinical trials.
Investigational
Matched Description: … the joints, fusion of fingers and toes, contraction of the mouth membranes and narrowing of the oesophagus ... It is developed by Cellerix and is in phase I of clinical trials. ... is used to treat epidermolysis bullosa (EB), a rare genetic condition which can lead to contraction of …
ND7001
ND7001, a selective PDE2 inhibitor is in clinical trials for the treatment of depression. ND7001 is a solid. Known drug targets of ND7001 including phosphodiesterase 2A, cGMP-stimulated and cGMP-dependent 3',5'-cyclic phosphodiesterase. It is a new type of antidepressant drug with anxiolytic activity. It is the first representative of a new...
Investigational
Matched Description: … It is the first representative of a new generation of psycho-active compounds potentially devoid of several ... It is a new type of antidepressant drug with anxiolytic activity. ... ND7001, a selective PDE2 inhibitor is in clinical trials for the treatment of depression. …
XEN-2174
XEN-2174 is a synthetic drug modeled on a peptide from the venom of a cone shell found on Australia's Great Barrier Reef. XEN-2174 represents a new class of molecules, called the chi conopeptides that selectively inhibit the Norepinephrine Transporter (NET). NET is the primary mechanism regulating the biological effects of...
Investigational
Matched Description: … In episodes of pain, inhibition of NET by XEN-2174 elevates the levels of NE leading to the activation ... of inhibitory pathways preventing pain signals from reaching the brain. ... XEN-2174 is a synthetic drug modeled on a peptide from the venom of a cone shell found on Australia's …
Managlinat dialanetil
CS-917 is a novel inhibitor of fructose 1,6-bisphphosphatase (FBPase) which is one of the rate-limiting enzymes of gluconeogenesis.
Investigational
Matched Description: … enzymes of gluconeogenesis. ... CS-917 is a novel inhibitor of fructose 1,6-bisphphosphatase (FBPase) which is one of the rate-limiting …
Rozrolimupab
Rozrolimupab is a recombinant polyclonal antibody consisting of 25 different anti-Rhesus D (RhD) antibodies to replace existing anti-RhD hyperimmune immunoglobulins for the treatment of Idiopathic Thrombocytopenic Purpura (ITP) and the prevention of Hemolytic Disease of Newborns (HDN).
Investigational
Matched Description: … Purpura (ITP) and the prevention of Hemolytic Disease of Newborns (HDN). ... Rozrolimupab is a recombinant polyclonal antibody consisting of 25 different anti-Rhesus D (RhD) antibodies ... to replace existing anti-RhD hyperimmune immunoglobulins for the treatment of Idiopathic Thrombocytopenic …
Dectrekumab
Dectrekumab is under investigation in clinical trial NCT00987545 (Efficacy 2 Part Study of Identification of Keloid Biomarkers and Effect of QAX576 on Keloid Recurrence).
Investigational
Matched Description: … of Keloid Biomarkers and Effect of QAX576 on Keloid Recurrence). ... Dectrekumab is under investigation in clinical trial NCT00987545 (Efficacy 2 Part Study of Identification …
AX200
AX200, which has been developed for the treatment of stroke, is the most advanced drug candidate and is halfway through the process of gaining clinical approval. The expression of the endogenous AX200 protein in the brain is increased after brain damage. Thus, if this drug administered in the acute phase...
Investigational
Matched Description: … stroke, while stimulating simultaneously the regeneration of nervous tissue through the induction of ... is halfway through the process of gaining clinical approval. ... neuro- and arteriogenesis and supporting the reorganisation of the nervous system. …
TAFA-93
TAFA93 is a novel prodrug of the mTOR inhibitor rapamycin which has successfully completed Phase 1 clinical development. mTOR inhibitors are currently used in the prevention of organ rejection in transplantation, the treatment of autoimmune and oncological diseases, and as a component of coated stents for the treatment of coronary...
Investigational
Matched Description: … of coronary artery disease. ... , the treatment of autoimmune and oncological diseases, and as a component of coated stents for the treatment ... TAFA93 is a novel prodrug of the mTOR inhibitor rapamycin which has successfully completed Phase 1 clinical …
ICA-105665
ICA-105665 is a novel small molecule compound for the treatment of epilepsy. It is a novel opener of the KCNQ ion channel which in preclinical studies has demonstrated a broad spectrum of activity in models of epilepsy. In addition, ICA-105665 has also demonstrated activity in certain models of neuropathic pain.
Investigational
Matched Description: … of activity in models of epilepsy. ... ICA-105665 is a novel small molecule compound for the treatment of epilepsy. ... In addition, ICA-105665 has also demonstrated activity in certain models of neuropathic pain. …
Sitimagene ceradenovec
Sitimagene ceradenovec is a novel gene-based product for the treatment of patients with operable high grade glioma, a type of malignant brain tumour, given in addition to standard surgery and radiotherapy/chemotherapy. It is being developed by Ark Therapeutics.
Investigational
Matched Description: … Sitimagene ceradenovec is a novel gene-based product for the treatment of patients with operable high ... grade glioma, a type of malignant brain tumour, given in addition to standard surgery and radiotherapy …
SC12267
SC12267 is a novel, small molecule agent from the class of DMARDs (disease modifying anti-rheumatic drug) for the therapy of autoimmune diseases such as rheumatoid arthritis or multiple sclerosis. Through highly selective inhibition of pyrimidine biosynthesis, it controls the growth of rapidly proliferating cells, especially of lymphocytes, which are important...
Investigational
Matched Description: … Through highly selective inhibition of pyrimidine biosynthesis, it controls the growth of rapidly proliferating ... cells, especially of lymphocytes, which are important for the immune response. ... ) for the therapy of autoimmune diseases such as rheumatoid arthritis or multiple sclerosis. …
Platelet Lysate
Platelet lysate is an acellular compound composed of platelet proteins while also being void of cellular debris, thus making the lysate rich with growth factors. It is extracted through lysis of the plasma membrane of platelets. Because white cell antigens are low in prepared lysate, there is a minimized likelihood...
Investigational
Matched Description: … [A220188] It is extracted through lysis of the plasma membrane of platelets. ... Platelet lysate is an acellular compound composed of platelet proteins while also being void of cellular ... Because white cell antigens are low in prepared lysate, there is a minimized likelihood of immune responses …
NP-50301
NP-50301 is an ophthalmic therapeutic eye drop treating post-menopausal Dry Eye Syndrome (DES). It is being developed by Nascent Pharmaceuticals. It is estimated that about 30% of postmenopausal women suffer symptoms of DES, which accounts for over 12 million women in the U.S. The majority of sufferers of DES are...
Investigational
Matched Description: … It is estimated that about 30% of postmenopausal women suffer symptoms of DES, which accounts for over ... The majority of sufferers of DES are postmenopausal women; and clinical research around the world has ... suggested the benefits of both topical and systemic estrogen therapy in the treatment of DES in this …
Chloropyramine
Chlorpyramine is a first generation antihistamine used in Eastern European countries to treat bronchial asthma as well as allergice rhinitis, allergic conjunctivitis, and other allergic reactions. It is also indicated for Quincke's edema, allergic reactions to insect bites, food and drug allergies, and anaphylactic shock.
Experimental
BMS-919373
BMS-919373 is under investigation in clinical trial NCT02153437 (Study of the Effects of BMS-919373 on the Electrical Activity of the Heart Using Pacemakers).
Investigational
Matched Description: … BMS-919373 is under investigation in clinical trial NCT02153437 (Study of the Effects of BMS-919373 on ... the Electrical Activity of the Heart Using Pacemakers). …
Maplirpacept
Maplirpacept is a recombinant fusion protein consisting of the CD47-binding domain of human signal regulatory protein alpha (SIRPa) linked to the IgG4 Fc region of human IgG.
Investigational
Matched Description: … Maplirpacept is a recombinant fusion protein consisting of the CD47-binding domain of human signal regulatory ... protein alpha (SIRPa) linked to the IgG4 Fc region of human IgG. …
NS-2359
NS2359 is a triple monoamine re-uptake inhibitor with a new, unique drug profile expected to yield important benefits compared to existing treatments of depression. Enhancing the function of the three neurotransmitters serotonin, noradrenalin and dopamine, NS2359 has a desired "triple-mode-of-action". This mode of action is expected to produce an optimal...
Investigational
Matched Description: … of an earlier onset of action compared to antidepressants already on the market. ... a desired "triple-mode-of-action". ... with a new, unique drug profile expected to yield important benefits compared to existing treatments of …
Plozalizumab
Plozalizumab has been investigated for the treatment of Atherosclerosis. Plozalizumab, a novel humanized monoclonal antibody, specifically targets CCR2 chemokine receptors found on the surface of certain white blood cells including macrophages and monocytes. Preclinical studies suggest that CCR2 plays an important role in the trafficking of monocytes and macrophages to...
Investigational
Matched Description: … of atherosclerosis. ... to sites of inflammation. ... Plozalizumab has been investigated for the treatment of Atherosclerosis. …
Ciraparantag
Ciraparantag is under investigation in clinical trial NCT01826266 (Effects of a Double-Blind, Single Dose of PER977 Administered Alone, and Following a Single Dose of Edoxaban).
Investigational
Matched Description: … Dose of PER977 Administered Alone, and Following a Single Dose of Edoxaban). ... Ciraparantag is under investigation in clinical trial NCT01826266 (Effects of a Double-Blind, Single …
Go-6976
An inhibitor of calcium-dependent isoforms of protein kinase C.[A253002,A253007]
Investigational
Matched Description: … An inhibitor of calcium-dependent isoforms of protein kinase C.[A253002,A253007] …
ATL1101
ATL1101 is a second-generation antisense drug designed to block the synthesis of the IGF-1 receptor, a protein involved in the regulation of cell overgrowth in psoriasis. ATL1101 is being developed as a cream for the topical treatment of mild to moderate cases of psoriasis.
Investigational
Matched Description: … ATL1101 is being developed as a cream for the topical treatment of mild to moderate cases of psoriasis ... a protein involved in the regulation of cell overgrowth in psoriasis. ... ATL1101 is a second-generation antisense drug designed to block the synthesis of the IGF-1 receptor, …
Displaying drugs 10176 - 10200 of 12422 in total